X.T.L. Biopharmaceuticals Partners with Eurofarma to Revolutionize Epilepsy Management Through AI

Innovative Venture in Epilepsy Management: SK Biopharmaceuticals Partners with Eurofarma

In a significant development for digital healthcare, SK Biopharmaceuticals, a company renowned for its advancements in treatments for central nervous system disorders, announces the formation of a new joint venture, Mentis Care, Inc., in partnership with Brazilian pharmaceutical firm Eurofarma. The official launch event takes place in Toronto, Canada, on October 20, 2025, marking a strategic pivot for SK Biopharmaceuticals into the realm of digital health solutions. This collaboration represents a concerted effort to harness artificial intelligence (AI) and wearable technology to transform the management of epilepsy, a condition that affects millions worldwide.

Mentis Care is set to develop an innovative AI-driven platform designed for epilepsy management, utilizing the companies’ extensive expertise in AI-powered electroencephalography (EEG) and wearable technologies. Since 2018, SK Biopharmaceuticals has focused on refining these technologies, and the joint venture aims to leverage this groundwork to create a robust system for real-time seizure detection and monitoring. By integrating clinical decision support tools, Mentis Care plans to offer a comprehensive digital platform that facilitates personalized patient care, thereby enhancing the overall management of epilepsy.

Located in the MaRS Discovery District—a prominent innovation hub in Toronto—Mentis Care has ambitious plans for growth and collaboration. The venture intends to expand its team and actively seek partnerships with both academic institutions and industry stakeholders to validate its AI algorithms clinically. This initiative represents a pivotal moment for SK Biopharmaceuticals, as it seeks to revolutionize epilepsy care through cutting-edge technology, ultimately aiming to improve patient outcomes and redefine the landscape of healthcare solutions for this chronic condition.

In addition to its core focus on epilepsy management, the formation of Mentis Care underscores SK Biopharmaceuticals' commitment to enhancing its portfolio in digital health. The collaboration with Eurofarma not only expands its geographical reach but also emphasizes the importance of integrating technological advancements in traditional healthcare approaches. As the digital health sector continues to evolve, SK Biopharmaceuticals is poised to play a significant role in shaping innovative solutions that address complex medical challenges.

With the establishment of Mentis Care, SK Biopharmaceuticals is positioned to make a lasting impact on the future of epilepsy treatment. By combining its strengths in neuroscience with advanced AI technologies, the joint venture is set to lead the charge in improving healthcare delivery for epilepsy patients globally.